The Future of 
Vascular Bio-Technology


Integene is a privately held biotechnology company based in Miami, Florida, developing a platform gene therapy technology capable of treating a broad base of vascular diseases, including peripheral arterial disease (PAD), coronary artery disease (CAD) and solid hypoxic tumors. The treatments are based on our proprietary "Gene Switch" technology for hypoxia-targeted gene expression.

The Company has an experienced management advisory team with a business strategy to focus first on optimized gene-based treatment and prevention strategies for PAD, developed in parallel with treatments for CAD and solid metastatic tumors.

Our goals are to advance the PAD indication to a Phase I/II clinical efficacy and safety study in 2018/19, then partner with a pharmaceutical company upon the achievement of positive clinical results (estimated in 2020). Treatments of CAD, heart failure and tumors using the same Gene Switch technology are being pursued in parallel. 

Website Builder